Novo Nordisk is seeking up to $830 million in damages from KBP Biosciences, according to a ruling by a Singapore court, as ...

Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...

Novo Nordisk has been looking to diversify its lineup in recent years, and is developing medicines in other fields. The ...

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...

Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

If you purchased Novo Nordisk securities during the Class Period you may be entitled to compensation without payment of any ...

Novo Nordisk reprimanded for allegedly failing to disclose payments - The manufacturer of the weight loss jab Wegovy said it ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Shares of weight loss and diabetes medication maker Novo Nordisk (NYSE: NVO) have slumped precipitously over the past 52 ...

Novo Nordisk's CEO took a $1.5 million pay cut in 2024 as the pharma giant's share price tanked and it missed profit and DEI ...